摘要
目的:探讨重组人白细胞介素-2序贯治疗高龄急性髓系白血病(AML)的临床疗效。方法:36例高龄患者随机分为治疗组及对照组,治疗组在对照基础上给予白介素-2治疗,对照组给予间断成分输血、抗感染及止血药物治疗。结果:2组治疗缓解率差异无统计学意义;治疗组治疗前后骨髓原始细胞百分率差异无统计学意义;治疗组中位OS为25.2周,对照组中位OS为11周,差异有统计学意义(P<0.05)。结论:白细胞介素-2序贯治疗高龄AML不能提高缓解率,但可延长生存期,可能是治疗高龄AML患者较好的非细胞毒性治疗方法。
Objective：To explore the clinical efficacy of sequential treatment with recombinant human interleukin-2（rhIL-2） in senior patients with acute myeloid leukemia（AML）.Method：Thirty-six senior patients with AML were randomly divided into therapeutic group and control group.Patients in the control group were given the interrupted component blood transfusion,anti-infection and pharmacological hematischesis therapy.Other patients in the therapeuic group were treated with rhIL-2.Result：The remission rate in two groups was not significantly different.The marrow blastic cell percentage was not significantly different between pre-and post-treatment in the therapeutic group.The median OS was 25.2 weeks in the therapeuic group,which was significantly different from that in the control group（11 weeks,P=0.0476）.Conclusion：The sequential treatment with rhIL-2 can not increase the remission rate,but can lengthen the lifetime in senior patients with AML.It is an alternative therapeutic method without cytotoxicity for senior patients with AML.
出处
《临床血液学杂志》
CAS
2011年第2期163-164,167,共3页
Journal of Clinical Hematology
